SystImmune to Unveil Promising Data on iza-bren for Small Cell Lung Cancer at ELCC 2026 SystImmune, Inc. is set to present new findings on iza-bren, an innovative treatment for extensive stage small cell lung cancer at ELCC 2026.

SystImmune to Unveil Promising Data on iza-bren for Small Cell Lung Cancer at ELCC 2026 #United_States #SystImmune #Redmond #Lung_Cancer #Iza-bren

SystImmune Affiliate Biokin to Showcase Innovations at J.P. Morgan Healthcare Conference SystImmune, a clinical-stage biotech firm, announces Biokin will present at J.P. Morgan's 44th Annual Healthcare Conference on January 15, 2026.

SystImmune Affiliate Biokin to Showcase Innovations at J.P. Morgan Healthcare Conference #United_States #Healthcare_Conference #SystImmune #Redmond #Biokin

SystImmune's Iza-bren Achieves Key Trial Milestone for NPC Patients at ESMO 2025 SystImmune has announced that their drug Iza-bren has met significant clinical endpoints in a major trial for NPC patients, a breakthrough presented at the ESMO Congress.

SystImmune's Iza-bren Achieves Key Trial Milestone for NPC Patients at ESMO 2025 #USA #SystImmune #Redmond #NPC #Iza-bren

SystImmune and Bristol Myers Squibb Reveal Iza-bren Phase I Study Results for Advanced Tumors SystImmune and Bristol Myers Squibb announce successful Phase I results of Iza-bren for advanced solid tumors at ESMO 2025, showcasing safety and efficacy.

SystImmune and Bristol Myers Squibb Reveal Iza-bren Phase I Study Results for Advanced Tumors #United_States #SystImmune #Redmond #Iza-bren #Bristol_Myers

SystImmune Achieves Major Milestone with Bristol Myers Squibb Collaboration in Breast Cancer Study SystImmune announces a significant milestone in breast cancer treatment, receiving a $250 million payment from Bristol Myers Squibb for their Iza-Bren collaboration.

SystImmune Achieves Major Milestone with Bristol Myers Squibb Collaboration in Breast Cancer Study #USA #SystImmune #Redmond #Bristol_Myers_Squibb #Iza-bren

SystImmune to Showcase Innovative Cancer Treatments at ESMO 2025 SystImmune, Inc. will reveal pivotal clinical data on its innovative drug candidates, iza-bren and BL-M07D1, at ESMO 2025.

SystImmune to Showcase Innovative Cancer Treatments at ESMO 2025 #USA #SystImmune #Redmond #Iza-bren #BL-M07D1

SystImmune, Inc. to Showcase Promising New Iza-bren Data at WCLC 2025 SystImmune, Inc. is set to present vital new data on Iza-bren for non-small cell lung cancer at the 2025 WCLC conference, highlighting its efficacy.

SystImmune, Inc. to Showcase Promising New Iza-bren Data at WCLC 2025 #United_States #SystImmune #Redmond #Lung_Cancer #Iza-bren

SystImmune and Bristol Myers Squibb Secure Breakthrough Therapy Designation for Cancer Treatment SystImmune and Bristol Myers Squibb have received Breakthrough Therapy Designation for izalontamab brengitecan to treat advanced lung cancer, offering new hope to patients.

SystImmune and Bristol Myers Squibb Secure Breakthrough Therapy Designation for Cancer Treatment #United_States #SystImmune #Redmond #Izalontamab_Brengitecan #EGFR_Mutated_Lung_Cancer

Bristol's third pivotal iza-bren study

A very interesting bispecific ADC highlighted today by
@JacobPlieth on X
-
oncologypipeline.com/apexonco/bri...
while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune

Exploring New Potential of Iza-Bren in Combatting Advanced Lung Cancers SystImmune, Inc. will unveil new data on Iza-Bren targeting advanced lung cancers with specific genomic alterations at the ASCO 2025 conference.

Exploring New Potential of Iza-Bren in Combatting Advanced Lung Cancers #United_States #Cancer_Treatment #SystImmune #Redmond #Iza-bren

SystImmune, Inc. Reveals New Findings on Iza-bren for Breast Cancer at ESMO 2025 Conference At the ESMO Breast Cancer 2025 congress, SystImmune presents promising data about Iza-bren, a drug aimed at treating advanced breast cancer.

SystImmune, Inc. Reveals New Findings on Iza-bren for Breast Cancer at ESMO 2025 Conference #USA #Breast_Cancer #SystImmune #Redmond #Iza-bren

SystImmune's Promising BL-B01D1 Data for Breast Cancer at 2024 SABCS SystImmune, Inc. is set to present new clinical data for BL-B01D1, an innovative breast cancer treatment, at the upcoming SABCS 2024 in Texas.

SystImmune's Promising BL-B01D1 Data for Breast Cancer at 2024 SABCS #United_States #San_Antonio #Breast_Cancer #SystImmune #BL-B01D1

SystImmune to Present Innovative CD33 Antibody-Drug Conjugate at ASH 2024 Meeting SystImmune, Inc. will present initial findings on BL-M11D1, an antibody-drug conjugate targeting CD33 in relapsed/refractory AML at ASH 2024.

SystImmune to Present Innovative CD33 Antibody-Drug Conjugate at ASH 2024 Meeting #United_States #San_Diego #SystImmune #BL-M11D1 #Acute_Myeloid_Leukemia